#USA #Atlanta #Cardiovascular #Nyra Medical #CARLEN System

Nyra Medical Strengthens Leadership Team

Nyra Medical, a prominent innovator in the field of structural heart therapies, has taken significant steps to enhance its executive team by appointing two seasoned professionals. These strategic hires are crucial as the company accelerates the development of its groundbreaking Cardiac Leaflet Enhancer (CARLEN) System, which aims to revolutionize treatment for patients with functional mitral regurgitation.

Key Appointments

On May 27, 2025, Nyra Medical announced the appointment of Jennifer Mischke as Vice President of Regulatory and Clinical Affairs, and Adam Martinez, Ph.D., as Vice President of Product Development. Their combined expertise is expected to propel the company toward new clinical and commercial milestones.

Jennifer Mischke’s Expertise

Jennifer Mischke is bringing over 20 years of leadership in regulatory affairs and clinical research to Nyra. With an extensive background that includes guiding cardiovascular and structural heart therapies through intricate regulatory processes, Mischke’s experience will play a pivotal role in supporting Nyra's strategy. Her knowledge in biostatistics, coupled with her experience working with global health authorities, positions her as an essential asset as the company transitions into its clinical-stage development. This move is particularly significant as Nyra seeks broader engagement with strategic partners and regulatory bodies to bring innovative solutions to patients suffering from complex heart conditions.

Adam Martinez’s Contributions

Dr. Adam Martinez is also a key addition to the team. With more than 15 years of experience in the structural heart sector, he has previously held important roles at Artivion where he significantly contributed to the advancement of next-generation cardiac and vascular technologies. His leadership has been instrumental in guiding global multidisciplinary teams through product development, engineering, and operations, resulting in obtaining crucial regulatory approvals. At Nyra, Dr. Martinez has been a driving force behind the CARLEN System, overseeing its journey from initial design and prototype testing to its current preclinical validations and leading clinical cases.

Industry Relevance

Nyra Medical has positioned itself at a critical juncture in its growth trajectory. According to CEO Lori Chmura, “These strategic appointments come at a critical juncture for Nyra. Jennifer's expertise in regulatory and clinical affairs brings a sophistication that is essential for our growth phase, while Adam’s technical depth has established a solid foundation for our current projects.”

This new leadership structure enables Nyra to not only meet the expectations of the medical device industry but also transcend them by potentially offering patients the hope of improved health outcomes through innovative treatment methods.

The CARLEN System

The CARLEN System is designed to address the challenge of functional mitral regurgitation through a minimally invasive approach. By effectively restoring proper leaflet coaptation, this novel technology aims to enhance the quality of care for patients affected by this complex and often debilitating condition. Nyra Medical continues to focus on its mission of redefining transcatheter repair for mitral regurgitation, with the CARLEN System being the centerpiece of this endeavor.

Conclusion

As Nyra Medical forges ahead, the appointments of Mischke and Dr. Martinez signal a commitment to advancing innovative heart therapies. Their leadership and industry experience will be crucial as Nyra aims to fulfill its promise of improving patient outcomes in cardiovascular care. With the CARLEN System nearing clinical validation, the future holds great potential for both Nyra Medical and the patients it serves.

For more information about Nyra Medical’s initiatives and the CARLEN System, visit nyramedical.com.